Umdlavuza wesibindi ubangela ngo-2026: Ukwelashwa nezindleko zaseChina - Izibhedlela eziseduze nami 

Izimbangela zomdlavuza wesibindi ngo-2026 ngokuyinhloko kuhlanganisa izifo ezingelapheki ze-hepatitis B no-C, isifo sesibindi esihlobene notshwala, isifo sesibindi esinamafutha angenalo utshwala (NAFLD), kanye nokuchayeka kuma-aflatoxin. E-China, imbangela ehamba phambili isalokhu i-Hepatitis B engapheli, ishayela indawo yokwelapha eyingqayizivele ehlanganisa ukwelashwa okuthuthukisiwe kokuzivikela komzimba, ukuhlinza okunembile, kanye nezinhlelo zomshwalense zikazwelonke ezingabizi kakhulu. Ukuqonda lezi zimbangela kubalulekile ekutholakaleni kusenesikhathi kanye nokufinyelela ekwelashweni kwakamuva kwemikhakha eminingi etholakala ezikhungweni zezokwelapha ezinkulu zaseShayina.

Izimbangela Zomdlavuza Wesibindi Eziyinhloko kanye Nezinto Zobungozi ngo-2026

I-etiology ye-hepatocellular carcinoma (HCC) isivele yavela, nokho isifo sokusha kwesibindi sohlobo lwe-viral sisalokhu sihamba phambili emhlabeni futhi ikakhulukazi e-Asia. Ngo-2026, ukuvumelana kwezokwelapha kugqamisa i-paradigm eguqukayo lapho izici ze-metabolic zikhuphuka ngokushesha kanye nezimbangela zegciwane lendabuko.

I-Chronic Viral Hepatitis: Umholi Ophikelelayo

Ukutheleleka okungapheli ngegciwane le-Hepatitis B (HBV) kuyisici esiyingozi kakhulu somdlavuza wesibindi eChina. Ngokungafani namazwe aseNtshonalanga lapho i-Hepatitis C noma utshwala buvame kakhulu, i-HBV ibangela izimo eziningi esifundeni. Igciwane lihlanganisa i-genome ye-host, ibangele ukuvuvukala okungapheli kanye ne-cirrhosis, okuholela ekuguqulweni okubi.

• I-Hepatitis B: Ibhekele cishe u-70-80% wamacala e-HCC e-China. Ukudluliselwa okuqondile kusuka kumama kuya enganeni kuseyisici esingokomlando, nakuba izinhlelo zokugoma zinciphise ukutheleleka okusha ezizukulwaneni ezincane.
• I-Hepatitis C: Nakuba ingavamile kune-HBV e-China, iseyimbangela ebucayi. Izidambisigciwane ezisebenza ngokuqondile (ama-DAAs) ziye zathuthukisa izinga lokwelapha, kodwa iziguli ezine-cirrhosis eqinisekisiwe zihlala zisengozini ngisho nangemva kokuvunyelwa kwegciwane.

Imihlahlandlela yakamuva igcizelela ukuthi i-viremia yezinga eliphansi ezigulini ezilashwa ngama-nucleos(t)ide analogues isengaba yingozi. Ucwaningo olwanyatheliswa ekuqaleni kuka-2026 lubonisa ukuthi ngisho neziguli ezelashwe nge-antiviral yomugqa wokuqala zingase zibe ne-viremia esezingeni eliphansi, okudinga ukuqapha okuqaphile ukuze kuvinjelwe ukuqhubekela phambili komdlavuza.

Ukungasebenzi kahle kweMetabolic kanye ne-NAFLD

Imbangela ekhula ngokushesha yomdlavuza wesibindi ngo-2026 i-Non-Alcoholic Fatty Liver Disease (NAFLD), manje esivame ukubizwa ngokuthi I-Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Njengoba izinguquko zendlela yokuphila zenzeka kulo lonke elaseShayina, ukukhuluphala kanye nohlobo 2 lwesifo sikashukela kuye kwanda.

Lokhu kushintsha kwe-metabolic kudala isibalo esisha sabantu abanomdlavuza wesibindi abangenaso isifo sokusha kwesibindi kohlobo lwe-viral. Umshini uhilela ukuvuvukala okungapheli kwebanga eliphansi kanye nokucindezeleka okwenziwe nge-oxidative ngaphakathi kwediphozi yamafutha esibindi. Lo mkhuba ukhombisa amaphethini omhlaba wonke kodwa uyakhula ngesivinini kubantu baseShayina basemadolobheni ngenxa yokushintsha kokudla kanye nempilo yokunganyakazi.

Isifo Sesibindi Esihlobene Notshwala kanye Ne-Aflatoxins

Ukuphuza ngokweqile kusaqhubeka nokuba nomthelela omkhulu. Utshwala busebenza ngokubambisana ne-viral hepatitis, buphindaphinda kakhulu ingozi yokuthuthukisa i-HCC. Uma isiguli sinakho kokubili i-HBV engapheli kanye nokusetshenziswa kotshwala obunzima, amathuba okuba nomdlavuza ayanda kakhulu uma kuqhathaniswa nokuba nesici sobungozi kuphela.

Ukwengeza, ukuchayeka kokudla kuma-aflatoxins, izinhlanganisela ezinobuthi ezikhiqizwa isikhunta kuzinhlamvu namantongomane agcinwe ngokungafanele, kusalokhu kukhathaza ezifundeni ezithile. I-Aflatoxin B1 iyi-carcinogen enamandla ebangela ukuguqulwa okuthile kufuzo lokucindezela isimila se-TP53. Nakuba imithethonqubo yokuphepha kokudla isithuthukile, lesi sici sendawo ezungezile sisenomthelela omkhulu emthwalweni wezifo ezindaweni zasemakhaya.

I-China's 2026 Treatment Landscape Nemihlahlandlela

I-China iqhamuke njengomholi womhlaba wonke ocwaningweni lomdlavuza wesibindi kanye nezindlela ezintsha zokwelapha. Ukukhululwa kwe- Izinkombandlela Zokuhlonza Umdlavuza Wesibindi kanye Nezokwelapha (Ushicilelo luka-2026) iphawula ingqopha-mlando ebalulekile. Le mihlahlandlela ihlanganisa ubufakazi bekhwalithi ephezulu obuvela ezivivinyweni zomtholampilo eziholwa yi-China, enikeza "Isixazululo Sikazwelonke" esifanelana ne-epidemiology ethile yesifunda.

Izinkombandlela Zikazwelonke Ezintsha (Ushicilelo luka-2026)

Ikhishwe ngasekuqaleni kuka-2026, imihlahlandlela kazwelonke ebuyekeziwe igcizelela imikhuba esekelwe ebufakazini esekelwe kudatha yasekhaya. Iminyaka engaphezu kweshumi, le mihlahlandlela iye yavela ukuze ibonise izici ezihlukile zeziguli zaseShayina, ezivame ukuba nezigaba zezifo ezithuthuke kakhulu kanye nokutheleleka kwe-HBV okucashile.

Inguqulo yango-2026 ihlanganisa ngokuhlelekile imiphumela yakamuva yocwaningo lomtholampilo lwekhwalithi ephezulu, okuhlanganisa nokutholwe kwangempela okushicilelwe kumajenali wamazwe ngamazwe yizazi zaseShayina. Lokhu kuqinisekisa ukuthi izincomo zokwelashwa azigcini nje ngokuzivumelanisa nezimo zezivumelwano zaseNtshonalanga kodwa zenzelwe izici zendawo zofuzo nezemvelo. Imihlahlandlela iqinisa umgomo wokuphatha "ithimba le-multidisciplinary" (MDT) njengezinga lokunakekela.

Ukuhlanganiswa Kwe-Immunotherapy kanye Nokwelashwa Okuhlosiwe

Ukwelashwa okuhleliwe komdlavuza wesibindi osethuthukile sekunoguquko. Izibuyekezo zesiteji ze-2026 Barcelona Clinic Liver Cancer (BCLC), ezihunyushwa ngochwepheshe abaphambili baseShayina, ziqinisa isikhundla sokwelapha okuhlanganisa amasosha omzimba njengendinganiso yokuqala yesifo se-Stage C.

• Izinga Lomugqa Wokuqala: Inhlanganisela yama-immune checkpoint inhibitors (njengama-PD-1 monoclonal antibodies) ane-tyrosine kinase inhibitors (njenge-sorafenib noma i-lenvatinib) manje isiyizinga legolide.
• Imithetho ethile: Idatha yomtholampilo isekela ukusetshenziswa kwe-PD-1 inhibitors ehlanganiswe ne-lenvatinib noma i-sorafenib, ebonisa ukusinda okuphelele okungaphezulu uma kuqhathaniswa ne-monotherapy.

Ucwaningo olwethulwa ekuqaleni kuka-2026 lugqamisa ukusebenza kwalezi zinhlanganisela ngisho nasezigulini ezinomsebenzi wesibindi se-Child-Pugh B, iqembu phambilini elalibhekwa njengelintekenteke kakhulu ekwelapheni okunolaka kwe-systemic. Lokhu kwandiswa kokufaneleka kokwelashwa kunikeza ithemba kubantu abaningi beziguli.

I-Neoadjuvant ne-Conversion Therapy Consensus

Impumelelo enkulu ku-hepatology yaseShayina ukwenziwa ngokusemthethweni kwamasu okwelapha ama-neoadjuvant kanye nokuguqula. I Ukuvumelana Kochwepheshe BaseShayina Nge-Neoadjuvant kanye Nokuguqulwa Kokwelashwa Kwe-Hepatocellular Carcinoma (izibuyekezo zika-2024/2026), eshicilelwe kumajenali asezingeni eliphezulu njenge Umdlavuza wesibindi, inikeza umhlahlandlela wokuguqula izimila ezingasahleki zibe yizo ezikhiphekayo.

Njengoba kunikezwe ukuthi u-70-80% weziguli zaseShayina zitholakala ezigabeni ezimaphakathi noma ezithuthukile lapho ukuhlinzwa kungenzeki ekuqaleni, ukwelashwa kokuguqula kubalulekile. Le ndlela isebenzisa ukwelashwa kwe-systemic ukunciphisa izimila, okuvumela ukukhishwa kokwelapha okulandelayo. Ukuvumelana kuchaza indlela ecacile yokukhetha isiguli, imijikelezo yokwelashwa, kanye nesikhathi sokuhlinzwa, ukunciphisa amazinga okuphinda afinyelele ku-70% ngokomlando phakathi neminyaka emihlanu ngemva kokuhlinzwa.

Amasu Okuhlinza Okuthuthukile kanye Nokungenelela

Ukuhlinzwa kusewukuphela kwendlela yokwelapha umdlavuza wesibindi osanda kuqala. Kodwa-ke, incazelo yegama elithi "resectable" inwetshiwe ngenxa yokuhlolwa okungcono kwangaphambi kokuhlinzwa kanye nemithi yokwelapha ehambisanayo. Izikhungo ezihamba phambili e-China zisebenzisa ubuchwepheshe obusezingeni eliphezulu ukuze kwandiswe imiphumela.

Ukususwa Okunembile Nokufakelwa Kwesibindi

Izikhungo zezokwelapha ezinkulu, njengeHepatobiliary and Pancreatic Center esibhedlela saseBeijing Tsinghua Changgung, zisebenzisa izindlela zokwelashwa ezinembayo. Odokotela abahlinzayo abafana no-Academician Dong Jiahong bahola amaqembu enza ukuhlinza okuyinkimbinkimbi ngokulahleka kwegazi okuncane kanye nezikhathi zokululama ngokushesha.

Ukufakelwa kwesibindi kugcinelwe iziguli ezihlangabezana nemibandela ethile (njengemibandela ye-Hangzhou noma imibandela ye-UCSF), ngezinye izikhathi ehlanganisa kakhulu kunenqubo evamile ye-Milan ukuze kuhlangatshezwane nevolumu ephezulu yamacala ahlobene ne-HBV e-China. Ukuhlanganiswa kwe-antiviral prophylaxis post-transplant kunciphise kakhulu izilinganiso zokuphinda kubamukeli abane-HBV abane-HBV.

I-Innovative Radiotherapy: I-Lattice ne-SBRT

Ukwelashwa ngemisebe kushintshile kusukela esilinganisweni sokudambisa kuya endleleni yokwelapha. Isibuyekezo sika-2026 BCLC sihlanganisa ngokusobala i-Stereotactic Body Radiation Therapy (SBRT) kanye ne-Transarterial Radioembolization (TARE) njengezinketho zokwelapha eziqinile ezigulini zeSigaba 0/A ezingazohlinzwa noma zikhishwe.

Abacwaningi baseShayina baphayona “I-Lattice Radiotherapy” yezimila ezinkulu ezingabaleki (≥10 cm). Le nqubo ihambisa imithamo ephezulu kakhulu yemisebe ezindaweni ezithile ngaphakathi kwesimila kuyilapho ilondoloza izicubu ezinempilo ezizungezile. Idatha yangaphambi kwesikhathi yomtholampilo eyethulwe eMhlanganweni Wonyaka we-ASCO wango-2026 iphakamisa amaphrofayili athembisayo okuphepha nempumelelo lapho ehlanganiswa nokwelashwa kwe-systemic.

Intuthuko ye-Interventional Radiology

I-Transarterial Chemoembolization (TACE) iseyinsika yesifo sesigaba esiphakathi (BCLC B). Kodwa-ke, imihlahlandlela yango-2026 ixwayisa ngokuhlanganiswa okujwayelekile kwe-TACE nokwelashwa kwesistimu ngaphandle kwezivivinyo zomtholampilo, iphawula ukuthi ubufakazi bamanje abuyisekeli jikelele le ndlela kuwo wonke amaqeqebana.

Ama-ejenti amasha e-embolic kanye nobuhlalu obuhlanza izidakamizwa kusetshenziswa ukuthuthukisa ukuphendula kwesimila. Ngaphezu kwalokho, umqondo "wokufuduka kwesigaba sokwelashwa" uvumela odokotela ukuthi bashintshe ngamandla phakathi kwe-TACE, ukwelashwa kwesistimu, nokuhlinzwa okusekelwe ekuphenduleni kwesimila, ukuqinisekisa ukuthi iziguli zithola ukungenelela okufanele kakhulu.

Ukuthola Izibhedlela Nochwepheshe Eduze Kwawe e-China

Ukuthola ukunakekelwa kwekhwalithi ephezulu kudinga ukwazi ukuthi izikhungo zokwenza kahle zitholakala kuphi. I-China inezikhungo ezimbalwa ezisezingeni lomhlaba ze-hepatobiliary ezifakwe ubuchwepheshe bamuva kanye namaqembu ahlukahlukene.

Izikhungo eziphezulu ze-Hepatobiliary

Isibhedlela saseBeijing Tsinghua Changgung: Lesi sikhungo siholwa nguSolwazi u-Dong Jiahong, sidume ngokuhlinzwa kwesibindi okuyinkimbinkimbi kanye nokufakelwa izitho zomzimba. Ithimba lihlanganisa ochwepheshe abafana noDkt. Lu Qian kanye noDkt. Xiang Canhong, abasebenza ngokukhethekile ekuhlinzeni kabusha nokuphatha imikhakha eminingi. Bahlinzeka ngemitholampilo eyisipesheli yamacala anzima, okuhlanganisa lawo anokuhlasela kwemithambo.

I-Fudan University Zhongshan Hospital (Shanghai): Ihabhu locwaningo lomdlavuza wesibindi kanye nokusetshenziswa komtholampilo. Ngaphansi kokuqondisa kochwepheshe abafana noSolwazi u-Gao Qiang, lesi sibhedlela sibalulekile ekubumbeni imihlahlandlela kazwelonke nasekusebenziseni uhlaka olusha lokuthatha izinqumo lwe-CUSE. Ingumholi ekuhlanganiseni i-radiology yokungenelela ne-systemic therapy.

Isibhedlela sase-Zhongnan sase-Wuhan University: Yaziwa ngokuthuthuka kwayo ku-radiotherapy kanye ne-chemoradiotherapy yamathumba amathambo nezicubu ezithambile kanye nomdlavuza we-hepatobiliary. Izethulo zabo zakamuva ku-ASCO zigqamisa izinto ezintsha ku-lattice radiotherapy kanye nezifundo zokuhlelwa kabusha kwe-metabolic.

Ungafinyelela Kanjani Ukunakekelwa

Izibhedlela eziningi ezisezingeni eliphezulu eChina zisebenza ngohlelo lokuqokwa. Iziguli zingabhukha ukubonisana ngama-akhawunti asemthethweni esibhedlela se-WeChat, izinhlelo zokusebenza ezizinikele, noma izingcingo zocingo. Ezigulini zamazwe ngamazwe noma lezo ezivela ezifundazweni ezikude, izikhungo eziningi zinikeza ukubonisana kokuqala kwe-telemedicine ukuze kubuyekezwe imaging kanye ne-pathology ngaphambi kohambo.

• Isinyathelo 1: Qoqa wonke amarekhodi ezokwelapha, okuhlanganisa izikena ze-CT/MRI (ku-DICOM CD), imibiko yokugula, nemiphumela yokuhlolwa kwegazi (ikakhulukazi i-AFP nesibindi).
• Isinyathelo sesi-2: Xhumana nomnyango wezokwelapha wamazwe ngamazwe wesibhedlela noma usebenzise inkundla yedijithali esemthethweni ukuze ubhalisele uchwepheshe we-Hepatobiliary Surgery noma I-Hepatology.
• Isinyathelo sesi-3: Ngena emtholampilo weThimba elihlukahlukene (MDT) uma ukhona. Lokhu kuqinisekisa ukuthi odokotela abahlinzayo, izazi ze-oncologists, kanye nezazi ze-radiologist zibuyekeza icala ndawonye ukuze benze uhlelo olungcono kakhulu.

Izindleko Zokwelashwa Nokuphathwa Komshuwalense ngo-2026

Izindleko zokwelashwa komdlavuza wesibindi e-China ziyehluka kakhulu kuye ngesigaba sesifo, ukwelashwa okukhethiwe, kanye nesigaba sesibhedlela. Kodwa-ke, uhlelo lwezokuphepha lwezempilo lukazwelonke oluqinile lwenze ukwelashwa okuthuthukile kwafinyeleleka kakhulu.

Ukwehlukaniswa kwezindleko zokwelashwa

Ukukhishwa kabusha kokuhlinzwa: Izindleko ze-hepatectomy ejwayelekile zisukela ku-40,000 kuya ku-80,000 RMB ($5,500 – $11,000 USD). Ukuhlinzwa okuyinkimbinkimbi okubandakanya ukwakhiwa kabusha kwemithambo noma izindlela ze-laparoscopic/robotic kungase kubize phakathi kuka-80,000 no-120,000 RMB.

Ukufakelwa Kwesibindi: Lena inketho ebiza kakhulu, ngokuvamile esukela ku-400,000 kuya ku-600,000 RMB ($55,000 – $83,000 USD). Lokhu kuhlanganisa ukuhlinzwa, izimali zokuthola izitho zomzimba, nokulaliswa esibhedlela kokuqala. Imithi yesikhathi eside ye-immunosuppressive yengeza ezindlekweni eziqhubekayo.

Ukwelashwa Kwesistimu: Ngaphambi kwezingxoxo zakamuva, izidakamizwa ezihlosiwe kanye ne-immunotherapies bekubiza kakhulu. Ngo-2026, ngenxa yokuthengwa kwezimpahla okusekelwe kumthamo kazwelonke (VBP) nokufakwa ohlwini Lukazwelonke Lwezidakamizwa Ezibuyiselwayo (NRDL), izindleko zehle kakhulu. Izindleko zanyanga zonke ze-PD-1 inhibitors kanye nama-TKIs manje zingaba ngaphansi kuka-2,000 kuya ku-5,000 RMB ($280 – $700 USD) ezigulini ezifakwe umshwalense.

Izinqubomgomo Zokukhokhelwa Komshwalense

I-China's Basic Medical Insurance (BMI) ihlanganisa ingxenye ebalulekile yokwelashwa komdlavuza wesibindi. Izinga lokuhlinzekwa kwezindleko zeziguli ezilalisiwe ezibhedlela zikahulumeni ngokuvamile lingaphezu kuka-70% kubasebenzi basemadolobheni futhi libe ngaphansi kancane kubahlali basemaphandleni, kuye ngokuthi isifunda.

• Uhlu Lukazwelonke Lwembuyiselo Yezidakamizwa (NRDL): Inhlanganisela yomugqa wokuqala we-immunotherapy (isb., i-camrelizumab, i-sintilimab ehlanganiswe ne-apatinib noma i-rivoceranib) manje iyabuyiselwa. Lolu shintsho lwenqubomgomo lushintshile, okwenza ukwelashwa okujwayelekile kufinyeleleke kubantu abaningi.
• Umshwalense Wezifo Ezibucayi: Izikimu zomshwalense ezingezelelwe zihlinzeka ngezindleko ezengeziwe zezindleko zezempilo eziyinhlekelele, ziphinde zehlise izindleko eziphuma ephaketheni lemindeni.

Ezigulini zamazwe ngamazwe ezingaqinisekisiwe, izindleko zizoba phezulu njengoba zikhokha inani eliphelele lohlu. Kodwa-ke, ngisho nangenani eliphelele, ukwelashwa e-China ngokuvamile kubiza kakhulu uma kuqhathaniswa ne-US noma i-Europe, ngaphandle kokuyekethisa ikhwalithi yokunakekelwa noma ukufinyelela emithini yakamuva.

Ukuhlaziywa Okuqhathanisayo Kwamasu Okwelapha

Ukukhetha ukwelashwa okufanele kuncike esigabeni sesimila, ukusebenza kwesibindi, kanye nesimo sokusebenza kwesiguli. Ithebula elilandelayo liqhathanisa izindlela eziyinhloko ezitholakala e-China ngo-2026.

Uhlaka Lokwenza Izinqumo lwe-CUSE

Intuthuko ephawulekayo ngo-2026 ukwamukelwa kohlaka lwe-CUSE ekuthathweni kwezinqumo zomtholampilo. Ihlongozwe kuzinkombandlela ezibuyekeziwe ze-BCLC futhi yasekelwa ochwepheshe baseShayina, le modeli idlulela ngale kwama-algorithms aqinile iye endleleni egxile esigulini.

Ukuqonda Izilinganiso Ezine

Uhlaka lwe-CUSE luhlola izilinganiso ezine ezibalulekile ukuze liqondise Ithimba Lezobuciko Ezihlukahlukene (MDT):

• Ubunkimbinkimbi: Iyasivuma isimo se-multifactorial sesifo, sicabangela i-tumor biology, i-physiology yesibindi, kanye ne-comorbidities ngesikhathi esisodwa.
• Ukungaqiniseki: Ibhekana nokubikezela okungaqondakali kanye nemvelo ephindaphindayo yobufakazi bezokwelapha. Ivumela ukuguquguquka njengoba idatha entsha ivela ngesikhathi sokwelashwa.
• Isihloko: Ibona umehluko ngamunye endleleni odokotela neziguli ezibona ngayo ubungozi nezinzuzo. Ihlanganisa okuthandwa yisiguli kanye namagugu.
• Izici Zomzwelo: Icubungula umthelela ongokwengqondo, okuhlangenwe nakho kwesikhathi esidlule, nezinkolelo zomuntu siqu zesiguli kanye nethimba lokunakekela.

Lolu hlaka luqinisekisa ukuthi izinhlelo zokwelashwa azigcini nje ngokuba zilungile ngokwezibalo kodwa futhi ziyasebenza futhi zamukelekile esigulini ngasinye. Kuwusizo ikakhulukazi ezimeni ezihambisana nomngcele lapho kukhona izinketho eziningi zokwelapha, okusiza ukuzulazula kuhwebo phakathi kolaka kanye nekhwalithi yempilo.

Ucwaningo Olusafufusa Neziqondiso Zesikhathi esizayo

Izikhungo zocwaningo zaseShayina zineqhaza elikhulu ekuqondeni umhlaba wonke ngomdlavuza wesibindi. Izifundo zakamuva ezethulwe ezingqungqutheleni ezinkulu ezifana ne-ASCO 2026 zigqamisa izindlela ezimbalwa ezithembisayo.

I-Metabolic Reprogramming kanye ne-Ferroptosis

Abacwaningi bathola ukuthi izinguquko ze-metabolic ziqhuba kanjani ukuqhubeka komdlavuza. Ucwaningo oluvela esibhedlela sase-Wuhan Zhongnan luveze ukuthi ama-metabolites afana ne-alpha-ketoglutarate angadala i-ferroptosis (ukufa kwamaseli ancike ku-iron), athuthukise ukuzwela komdlavuza we-colorectal nesibindi emisebeni. Lokhu kuvula iminyango yemithi yokwelapha eyinhlanganisela elawula i-tumor metabolism ukuze kukhuliswe ukusebenza kahle kokwelashwa kwendabuko.

Amagciwane e-Oncolytic kanye ne-Novel Immunotherapies

Ama-immunotherapies amasha asathuthuka. Izivivinyo zomtholampilo ziphenya amagciwane e-oncolytic (afana ne-OH2) afakwa ngqo kumathumba, alandelwa ukuvinjwa kwe-systemic immune checkpoint. Idatha yesigaba sangaphambi kwesikhathi iphakamisa ukuthi le ndlela elandelanayo ingashukumisa impendulo eqinile yokulwa nesimila, ngisho nasezimilanjeni “ezibandayo” ngokuvamile ezingaphenduli ku-immunotherapy kuphela.

Ukubhekana ne-Colorectal Liver Metastases

Ngenkathi i-HCC igxile kakhulu, ukwanda komdlavuza we-colorectal (CRC) eChina kulethe ukunakwa kwe-Colorectal Liver Metastases (CRLM). Njengoba i-CRC iba umdlavuza wesibili ovame kakhulu e-China, amasu akhethekile e-CRLM abalulekile. Ukwelashwa kwendawo okuqinile kanye nokuphatha okuphelele kufakazela ukwandisa ukuphila kwalezi ziguli, ngokubhaliswa okubonisa ukuthi isibindi siyindawo evame kakhulu ye-CRC ye-metastasis.

Imibuzo Evame Ukubuzwa Ngomdlavuza Wesibindi e-China

Ingabe umdlavuza wesibindi uyelapheka ngo-2026?

Yebo, umdlavuza wesibindi usaqala ungelapheka ngokuhlinzwa, ukufakelwa isibindi, noma ukukhishwa. Ezigabeni ezithuthukile, kuyilapho “ukwelapha” kungavamile, umgomo uwukulawula isikhathi eside kanye nokwandiswa kokusinda. Ukufika kwezindlela zokwelapha ezisebenzayo zokuhlanganisa amasosha omzimba kuguqule i-HCC ethuthukisiwe yaba yisimo esingelapheki esilawulekayo ezigulini eziningi, okunezilinganiso ezingcono kakhulu zokusinda ezimaphakathi uma kuqhathaniswa neminyaka edlule.

Kubiza malini ukwelashwa komdlavuza wesibindi eChina?

Izindleko ziyahlukahluka kakhulu. Ukuhlinzwa okuyisisekelo kungase kubize cishe u-$6,000 USD, kuyilapho ukufakelwa okuyinkimbinkimbi kungadlula u-$80,000 USD. Kodwa-ke, ezakhamuzini zaseShayina ezinomshuwalense, izindleko eziphuma ephaketheni ziphansi kakhulu ngenxa yezinqubomgomo zokubuyisela. Izidakamizwa ezithuthukisiwe ezifana ne-PD-1 inhibitors manje sezithengeka, zibiza amakhulu ambalwa amadola ngenyanga ngemva komshwalense, okwenza ukwelashwa okusezingeni lomhlaba kufinyeleleke.

Yiziphi izimbangela eziyinhloko zomdlavuza wesibindi eChina?

Imbangela eyinhloko ukutheleleka nge-Hepatitis B okungamahlalakhona, okubangela izimo eziningi. Ezinye izimbangela ezibalulekile zihlanganisa i-Hepatitis C, ukuphuza ngokweqile, kanye nesifo sesibindi esinamafutha angenalo utshwala (NAFLD) esiqhutshwa ukukhuluphala kanye nesifo sikashukela. Ukuchayeka kwe-Aflatoxin kuhlala kuyisici esiyingozi ezifundeni ezithile.

Ngingathola ukwelashwa eShayina njengomuntu wangaphandle?

Nakanjani. Izibhedlela ezinkulu njengeBeijing Tsinghua Changgung Hospital kanye neFudan Zhongshan Hospital zineminyango yamazwe ngamazwe enakekela iziguli zakwamanye amazwe. Banikeza abaxhumanisi abakhuluma isiNgisi, usizo ngama-visa, nezinhlelo zokwelashwa eziklanyelwe. Nakuba ukuhlinzekwa komshwalense kungase kuhluke, ikhwalithi yokunakekelwa ifanelana namazinga omhlaba, ngokuvamile ngenani eliphansi eliphelele kunamazwe aseNtshonalanga.

Ukugcina

-Zwayo Izimbangela zomdlavuza wesibindi kuyisinyathelo sokuqala sokuvikela nokutholwa kusenesikhathi, ikakhulukazi ezindaweni ezisengozini enkulu njengeChina lapho i-Hepatitis B idlange khona. Ngo-2026, indawo yokwelashwa komdlavuza wesibindi e-China ibonakala ngokuqamba okusha okusheshayo, ukubuyekezwa kwemihlahlandlela eqinile, nokuzibophezela okuqinile ekwenzeni izindlela zokwelapha ezithuthukile zifinyeleleke. Kusukela ekwamukelweni okusabalele kwemithi yokuhlanganisa amasosha omzimba kuya ekuthuthukisweni kwamasu okuhlinza kanye nokuqaliswa kwezinhlaka zezinqumo ezigxile esigulini njenge-CUSE, i-China ibeka izilinganiso ezintsha ekunakekelweni kwe-hepatobiliary.

Iziguli namuhla zinezinketho eziningi kunangaphambili. Kungakhathaliseki ukuthi ngokuhlinzwa okwelaphayo, i-radiotherapy enembile, noma izindlela zokwelapha zesistimu ezinwetshwa ukuphila, ukuhlanganiswa kochwepheshe bemikhakha eminingi kuqinisekisa ukuthi isiguli ngasinye sithola uhlelo oluhambisanayo. Ngokusekelwa imishwalense kazwelonke enciphisa izithiyo zezimali, indlela esuka ekuxilongweni kuya ekusindeni icacile futhi inethemba. Kunoma ubani ofuna ukwelashwa, izikhungo ezisezingeni lomhlaba kanye namaqembu ochwepheshe e-China banikeza ukukhanya kwethemba, ukuhlanganisa isayensi esezingeni eliphezulu nokunakekela kozwela ukuze kuliwe nalesi sifo esesabekayo.